Moderna, Merck Shares Fall After Possible Melanoma Data Leak

What happened: Moderna and Merck shares fell after reports about results of their personalized melanoma vaccine emerged from unverified sources ahead of a scheduled presentation. Key numbers: Moderna fell as much as 25% on Thursday; Merck dropped 3.9%. One unverified report cited a 42% reduction in recurrence or death. Why it matters: The companies announced in August that the vaccines with Keytruda led to significant reductions in recurrence but provided no details, and the unverified figures appeared before the official data release. Market: -1.1% today ($148.26), +40.3% YTD, 1.6x vol — as of 19:17 UTC Coverage: 4 outlets in 24h

Moderna and Merck shares fell after reports about results of their personalized melanoma vaccine emerged from unverified sources ahead of a scheduled presentation.

The companies announced in August that the vaccines with Keytruda led to significant reductions in recurrence but provided no details, and the unverified figures appeared before the official data release. Market: -1.1% today ($148.26), +40.3% YTD, 1.6x vol — as of 19:17 UTC